Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WuXi PharmaTech's Leader Explains How U.S. Economic Tremors Tore Through American Subsidiary, Buried Five Years of Company Earnings

This article was originally published in PharmAsia News

Executive Summary

BEIJING - The leadership of WuXi PharmaTech, China's top contract research organization, has spelled out for the first time in detail how its ill-timed acquisition of an American biologics manufacturing and testing outfit, lashed by the tempests of the West's financial crisis, triggered a massive loss that wiped out five years of earnings

You may also be interested in...



How Much Risk Should Big Pharma Accept To Close Deals In China? (Part 2 of 2)

[Part 1 of this feature appeared Jan. 17 in PharmAsia News. Part 2 continues with the examination of China deals with Sanofi-Aventis' VP-Business Development Arjun Oberoi and Simcere President Yehong Zhang, who presented during the 29th annual J.P. Morgan Healthcare conference in San Francisco last week.]

How Much Risk Should Big Pharma Accept To Close Deals In China? (Part 2 of 2)

[Part 1 of this feature appeared Jan. 17 in PharmAsia News. Part 2 continues with the examination of China deals with Sanofi-Aventis' VP-Business Development Arjun Oberoi and Simcere President Yehong Zhang, who presented during the 29th annual J.P. Morgan Healthcare conference in San Francisco last week.]

WuXi PharmaTech Rebounds; Prepares For A Surge In China Biologics

WuXi PharmaTech founder Ge Li has plenty of reasons to feel good these days, despite a widely publicized failed merger with Charles River Laboratories. The largest Chinese pharmaceutical contract research organization not only posted record earnings for the third quarter, it also raised guidance for the full year

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC072134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel